Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 54903 in Asthma Inadequately Controlled on Low Dose ICS
NCT01458912Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2011
- Primary completion
- May 2013
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial of ciclesonide in asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mean change from baseline in evening trough Forced Expiratory Volume in 1 second at 12 weeks. Planned start Nov 2011; status: withdrawn.
02
Drugs
ciclesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01458912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458912.